Headache News and Research

Latest Headache News and Research

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

13 Jul 2011

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

St. Jude Medical, Inc., a global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for expansion of its BROADEN (BROdmann Area 25 DEep brain Neurostimulation) study for depression. This expansion will allow a maximum of 20 sites across the U.S. to enroll up to 125 patients.

11 Jul 2011

GlaxoSmithKline's Boostrix receives FDA approval to prevent tetanus, diphtheria, and pertussis

The U.S. Food and Drug Administration today approved Boostrix vaccine to prevent tetanus, diphtheria, and pertussis (whooping cough) in people ages 65 and older.

11 Jul 2011

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif in patients with relapsing-remitting multiple sclerosis.

11 Jul 2011

FDA approves BOOSTRIX to prevent tetanus, diphtheria and pertussis in older people

The U.S. Food and Drug Administration (FDA) has approved BOOSTRIX for use in adults 65 years of age and older for active booster immunization against tetanus, diphtheria and pertussis.

11 Jul 2011

Research roundup: Rural hospitals have poorer quality; Cost-effective migraine relief; Doctors still take Medicare

Quality Of Care And Patient Outcomes In Critical Access Rural Hospitals -- This study looks at the quality of care provided by patterns of care at "critical access hospitals," a federal designation for hospitals that serve rural populations and thus have been granted special incentives under Medicare.

8 Jul 2011

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).

From Baxter International Inc. 8 Jul 2011

Scientists track public health trends through Twitter

Twitter allows millions of social media fans to comment in 140 characters or less on just about anything: an actor's outlandish behavior, an earthquake's tragic toll or the great taste of a grilled cheese sandwich.

8 Jul 2011

Exploring trends in the doctor-patient relationship

News outlets report on recent developments — such as patients billing physicians for the time they spend waiting and how doctors are seeking help in dealing with difficult patients.

8 Jul 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

Exenatide tQT clinical trial meets pre-specified primary endpoint

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations.

8 Jul 2011

Treating migraines with behavioral approaches can make financial sense

Treating chronic migraines with behavioral approaches - such as relaxation training, hypnosis and biofeedback - can make financial sense compared to prescription-drug treatment, especially after a year or more, a new study found.

6 Jul 2011

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

VIVUS, Inc. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction.

30 Jun 2011

Almirall, Forest Labs submit aclidinium bromide NDA to FDA for treatment of COPD

Forest Laboratories, Inc. and Almirall, S.A. announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for aclidinium bromide, a long-acting inhaled antimuscarinic agent developed for the treatment of COPD.

30 Jun 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis (ranibizumab injection) in people with diabetic macular edema (DME).

29 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros Corporation today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells.

27 Jun 2011

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Over a decade ago, Canadian patients diagnosed with chronic myeloid leukemia (CML), celebrated when PrGleevec (imatinib mesylate) was approved in Canada.

27 Jun 2011

Headache News and Research

Latest Headache News and Research

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

GlaxoSmithKline's Boostrix receives FDA approval to prevent tetanus, diphtheria, and pertussis

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

FDA approves BOOSTRIX to prevent tetanus, diphtheria and pertussis in older people

Research roundup: Rural hospitals have poorer quality; Cost-effective migraine relief; Doctors still take Medicare

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Scientists track public health trends through Twitter

Exploring trends in the doctor-patient relationship

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Exenatide tQT clinical trial meets pre-specified primary endpoint

Treating migraines with behavioral approaches can make financial sense

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

Almirall, Forest Labs submit aclidinium bromide NDA to FDA for treatment of COPD

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in